A study of the inhibition of butyrylcholinesterase by dipotassium trioxohydroxytetrafluorotriborate K2[B3O3F4OH]

Alzheimer's is a disease that causes dementia disorders. Alzheimer's dementia is the most common form of dementia in modern society (affects more than 20 million people around the world). Currently, the only effective treatment for Alzheimer’s disease (AD) targets the cholinergic system using inhibitors of cholinesterase (ChE). Since only a small number of drugs for treatment of AD cognitive dysfunction and memory loss associated with AD (a few synthetic medicines, e.g. tacrine, donepezil and the natural product- based rivastigmin and galanthamine) exist, there is a great interest in finding new ChE inhibitors. Butyrylcholinesterase is an enzyme that acts as a natural cleaner compounds which inhibit acetylcholinesterase. It is possible that the various changes associated with cholinergic synapses and neurons and glial cells, increased in the brain in Alzheimer's disease suggests that the inhibition of BuChE (compared to AChE) could be more important in the progression of Alzheimer's disease.